Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$44.44
▼ $2.31 (-4.9%)
Market data updated: 09/20 11:52 AM
Fundamentals updated: 09/19/2026
News analyzed: 09/20/2026
Market Cap
$7.39B
Day Range
$44.29 - $46.75
52-Week Range
$44.27 - $86.74
Beta
—
Next Earnings
27.10.2026
Support
$44.27
Resistance
$64.44
IONS is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-28.0% (1Y)
Strengths: 7/32 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Insiders
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 33.8%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: -$53.99 vs. price $44.44 (-221.5%)
Fair Value
Signal tension
Growth scores strong (79/100), but fair-value analysis scores this stock as relatively expensive (38/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
36
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
10d ago · $56.05
Evidence: Narrative Gap moved from 12 to -20 day-over-day
What happened after
10d ago · $56.34
Evidence: Panic-selling score jumped from 10 to 36 day-over-day
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
79
Quality
42
Value
38
Momentum
6
Risk
34
Sentiment
56
Fundamental
26
Institutional
67
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Ionis Pharmaceuticals has centered on two contrasting developments: the failure of its pelacarsen drug (developed with Novartis) in a late-stage cardiovascular trial, which led to stock declines for both companies and raised broader concerns about the efficacy of similar treatments from competitors like Amgen and Eli Lilly; alongside this, Ionis secured FDA approval for ZANVASTRO, its first treatment for Alexander disease, marking a significant milestone in rare disease therapy. The company’s stock reacted negatively to the trial setback but also highlighted its pipeline diversity.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Ionis Pharmaceuticals, Inc.. News trend score: 56. Reason: 7 of the last 20 articles are positive, versus 6 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
48
🎯 Conviction (vs. Emotion)
37
Psychology
92
Fundamentals
26
Technical
6
Valuation
38
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Price (3M)
-40%
Market Narrative
35
Fundamental Reality
37
Narrative Gap
-2
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
IONS exhibits a fragmented psychological landscape with no dominant state, but **loss aversion** and **herding** are most pronounced. The 23.7% drop over three months and today’s underperformance relative to peers suggest investors are actively managing losses and avoiding laggards. Elevated volume (1.28x) without extreme momentum or volatility hints at disciplined liquidation rather than panic. The key question: *Is this behavior driven by fundamental concerns or pure risk-off positioning?*
Updated: 09/09/2026, 05:13 AM
👥 What the crowd believes
"Novartis' pelacarsen study failed to cut cardiovascular events, clouding prospects for the drug and highlighting portfolio challenges"
"Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, ‘Lp(a),’ in a large clinical trial"
"Ionis Drug Wins FDA Approval as First Alexander Disease Treatment"
🧠 Market Brain events driving this
📈 12D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 100/100
🔴 Weakest match
Gerald M. Loeb — 29/100
🗣️ Why do they disagree?
The methodologies for IONS split sharply between those who see cyclical or qualitative strengths and those who flag fundamental or risk concerns. Charles Mackay and the cycle-focused investors (Marks-Cycle, Nelson) score high because they view the stock as positioned favorably within a market or business cycle, avoiding mania or overvaluation. In contrast, Graham’s strict defensive criteria, Loeb’s risk aversion, and Livermore’s trend-following rule all produce low scores, warning against the stock’s volatility, perceived overvaluation, or alignment against prevailing market momentum. Meanwhile, Fisher and Lynch—who prioritize exceptional quality and growth—land in the middle, acknowledging potential but not seeing it as transformative enough to justify a strong buy. The divide underscores a tension between cyclical optimism and deep-value or risk-averse caution.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 100
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 99
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 97
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 94
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 60
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 58
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 57
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟡 55
Adequate but not exceptional liquidity
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 38
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 37
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 31
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 31
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 30
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 30
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 29
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (0 bullish · 11 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
98.3%
Operating Margin
-40.4%
Net Margin
-40.4%
EBITDA Margin
-40.4%
ROE
-78.0%
ROA
-10.8%
ROIC
—
EPS
-$2.38
Cash
$372.26M
Total Debt
$1.76B
Current Ratio
3.83
Debt/Equity
3.60
How is Fair Value calculated? →
Current Price
$44.44
Estimated Fair Value (DCF)
-$53.99
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-221.5%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
19.2%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 19.2% | $-381.32M | $-349.83M |
| 2 | 15.0% | $-438.47M | $-369.06M |
| 3 | 10.8% | $-485.94M | $-375.24M |
| 4 | 6.7% | $-518.32M | $-367.19M |
| 5 | 2.5% | $-531.28M | $-345.30M |
Base FCF (last actual year)
$-320.03M
Terminal Value
$-8.38B
Present Value of Terminal Value
$-5.45B
Enterprise Value
$-7.25B
Net Debt
$1.39B
Equity Value
$-8.64B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$3.06
Tangible Book Value per Share (Tangible NAV)
$3.06
Sentiment based on basic keywords (not AI) — 7 positive, 7 neutral, 6 negative out of the last 20 articles.
Yahoo · 19.9.2026
Yahoo · 18.9.2026
Yahoo · 18.9.2026
Yahoo · 17.9.2026
Yahoo · 17.9.2026
Yahoo · 16.9.2026
SeekingAlpha · 16.9.2026
SeekingAlpha · 16.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
Benzinga · 15.9.2026
Yahoo · 11.9.2026
Insider Monkey · 11.9.2026
SeekingAlpha · 11.9.2026
Yahoo · 11.9.2026
Insider Monkey · 11.9.2026
Yahoo · 10.9.2026
Insider Monkey · 10.9.2026
SeekingAlpha · 10.9.2026
SeekingAlpha · 10.9.2026
Ionis Pharmaceuticals, Inc. (IONS) currently has a StockIQ AI score of 36/100, rated "Weak". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
IONS currently scores 36/100 (Weak) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, IONS's estimated fair value is -$53.99, which is 221.5% below the current price of $44.44. This is one valuation model among several signals in the fair-value category, not a price target.
IONS's technical score is 6/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 33.8%; Earnings per share (EPS) growth: 21.7%; Free cash flow growth: 41.4%.
Based on the real signals StockIQ computed: Estimated fair value: -$53.99 vs. price $44.44 (-221.5%); Operating margin: -40.4% (negative); Net margin: -40.4% (negative).
StockIQ has no recorded dividend payment history for IONS.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 4 purchases and 2 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Birchler Brian | Other Transaction | 31.8.2026 | 58 | +58 | $51.31 |
| Monia Brett P | Other Transaction | 31.8.2026 | 98 | +98 | $51.31 |
| O'NEIL PATRICK R. | Other Transaction | 31.8.2026 | 63 | +63 | $51.31 |
| BENNETT C FRANK | Other Transaction | 31.8.2026 | 110 | +110 | $51.31 |
| Hayden Michael R | Open Market Purchase | 31.7.2026 | 5,000 | +5,000 | $51.60 |
| Hayden Michael R | Open Market Purchase | 31.7.2026 | 24,000 | +5,000 | $51.60 |
| Hayden Michael R | Open Market Purchase | 30.7.2026 | 15,000 | +15,000 | $53.38 |
| Hayden Michael R | Open Market Purchase | 30.7.2026 | 19,000 | +15,000 | $53.38 |
| HERMAN JOAN E | Exercise of Derivative Securities | 15.7.2026 | 5,220 | +5,220 | — |
| BERTHELSEN SPENCER R | Exercise of Derivative Securities | 15.7.2026 | 5,220 | +5,220 | — |
| Reikes Peter N | Grant/Award from Employer | 15.7.2026 | 3,399 | +3,399 | — |
| HANTSON LUDWIG | Grant/Award from Employer | 15.7.2026 | 3,399 | +3,399 | — |
| BERTHELSEN SPENCER R | Exercise of Derivative Securities | 15.7.2026 | 5,220 | -5,220 | — |
| HERMAN JOAN E | Exercise of Derivative Securities | 15.7.2026 | 5,220 | -5,220 | — |
| BERTHELSEN SPENCER R | Exercise of Derivative Securities | 15.7.2026 | 161,233 | +5,220 | — |
| BERTHELSEN SPENCER R | Exercise of Derivative Securities | 15.7.2026 | 2,301 | -5,220 | — |
| HERMAN JOAN E | Exercise of Derivative Securities | 15.7.2026 | 51,306 | +5,220 | — |
| HERMAN JOAN E | Exercise of Derivative Securities | 15.7.2026 | 2,301 | -5,220 | — |
| HANTSON LUDWIG | Grant/Award from Employer | 15.7.2026 | 3,399 | +3,399 | — |
| Reikes Peter N | Grant/Award from Employer | 15.7.2026 | 3,399 | +3,399 | — |
| BENNETT C FRANK | Open Market Sale | 7.7.2026 | 5,536 | -5,536 | $83.58 |
| Kordasiewicz Holly B. | Open Market Sale | 7.7.2026 | 362 | -362 | $84.30 |
| BENNETT C FRANK | Other Transaction | 7.7.2026 | 15,000 | -15,000 | — |
| Diaz Allene M. | Exercise of Derivative Securities | 7.7.2026 | 10,111 | +10,111 | $47.11 |
| Diaz Allene M. | Exercise of Derivative Securities | 7.7.2026 | 10,111 | -10,111 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
20,924,638 shares short as of 2026-08-31 · vs. 21,466,123 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
24.5% of trading volume this week was short selling, vs. 32.2% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology